NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
30 Sep 2014

CVRx® Receives CE Mark Approval of the Barostim neo System™ for the Treatment of Heart Failure

Minneapolis – September 29, 2014 – CVRx, Inc., a private medical device company, announced today it received CE Mark approval from the National Standards Authority of Ireland (NSAI) of the Barostim neo System™ for the treatment of heart failure.
22 Sep 2014

CVRx® Secures $15 Million Growth Capital Facility from Silicon Valley Bank

Minneapolis – September 22, 2014 – CVRx, Inc., a private medical device company, announced today it secured a $15 million growth capital debt facility from Silicon Valley Bank.
AM-Pharma closes €12.2m financing round<
16 Sep 2014

AM-Pharma closes €12.2m financing round

Ysios Capital joins Am Pharma's 12.2 million euro financing.
08 Sep 2014

European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601

Leuven (BELGIUM) – 8 September, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, announced today that the Paediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Paediatric Investigation Plan (PIP) for Cx601, a locally injected stem cell product in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn´s disease.
01 Sep 2014

TiGenix appoints Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation

Leuven (BELGIUM) – 1 September, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, announced today that it has appointed Dr Marie Paule Richard as the Company’s Chief Medical Officer, and Dr Mary Carmen Diez as its Vice President Medical Affairs and New Product Commercialisation.
28 Aug 2014

TiGenix Business and Financial Update for the First Half of 2014

Leuven, Belgium – 26 August, 2014 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, issued an update on business and financial progress in the first half of this year today.
01 Jul 2014

European Medicines Agency renews Marketing Authorisation for ChondroCelect

Leuven (BELGIUM) – 1 July, 2014 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that the Committee for Medicinal Products for Human Use (CHMP) has renewed for an additional five years its marketing authorisation for ChondroCelect in all of the 31 countries of the European Union (EU) and European Economic Area (EEA).
30 Jun 2014

TiGenix announces the clinical development of Cx611 in early rheumatoid arthritis and severe sepsis

Leuven, Belgium – 30 June, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it will develop its intravenous-administered allogeneic stem cell product, Cx611, for patients suffering from early rheumatoid arthritis and for patients suffering from severe sepsis, a potentially life-threatening complication of infection.
19 Jun 2014

Kala Pharmaceuticals Initiates Phase 3 Clinical Trial for Treatment of Post-­Surgical Ocular Inflammation and Phase 2 Clinical Trial in Dry Eye Disease

WALTHAM, Mass.,June 19, 2014--Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform, today announced the initiation of two clinical trials with its nanotechnology-based loteprednol etabonate MPP (LE-MPP) program, KPI-121.
10 Jun 2014

CVRx® Achieves Two Significant Milestones for its Heart Failure and Hypertension Businesses

Minneapolis – June 9, 2014 – CVRx, Inc., a private medical device company, announced today it achieved two significant milestones in its heart failure and hypertension businesses.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка